Search Results
Aug 07, 2025, 15:38 ET Intas Pharmaceuticals et Accord BioPharma deviennent l'un des plus grands fournisseurs mondiaux de pegfilgrastim avec l'acquisition d'UDENYCA®
fébrile. UDENYCA offre trois options d'administration conviviales pour le patient, auto-injecteur (AI), injecteur corporel (OBI) et seringue pré-remplie (PFS), offrant une flexibilité pour le traitement à domicile, en déplacement ou en milieu clinique. Depuis son lancement commercial, plus de 300 000 patients
More news about: Accord Healthcare
Aug 07, 2025, 10:04 ET Intas Pharmaceuticals y Accord BioPharma se convierten en los mayores proveedores mundiales de pegfilgrastim
neutropenia febril. UDENYCA ofrece tres opciones de administración cómodas para el paciente: autoinyector (AI), inyector corporal (OBI) y jeringa precargada (PFS), lo que proporciona flexibilidad para el tratamiento en casa, fuera de casa o en entornos clínicos. Desde su lanzamiento comercial, más de 300.000 pacientes
More news about: Accord Healthcare
Aug 07, 2025, 01:00 ET Intas Pharmaceuticals and Accord BioPharma Become One of the Largest Global Suppliers of Pegfilgrastim with Acquisition of UDENYCA®
febrile neutropenia. UDENYCA offers three patient-friendly administration options—autoinjector (AI), on-body injector (OBI), and prefilled syringe (PFS)—providing flexibility for treatment at home, on-the-go, or in clinical settings. Since its commercial launch, over 300,000 patients have been treated with
More news about: Accord Healthcare
Aug 06, 2025, 21:30 ET Energy Fuels Announces Q2-2025 Results
a total of 50,000 tonnes per annum ("tpa") of monazite, producing roughly 5,000 tpa of NdPr, 150 to 225 tpa of Dy, and 50 to 75 tpa of Tb. The Mill PFS referenced above can be viewed on the Company's website,
More news about: Energy Fuels Inc.
Aug 06, 2025, 10:29 ET Intas Pharmaceuticals and Accord BioPharma Become One of the Largest Global Suppliers of Pegfilgrastim with Acquisition of UDENYCA®
febrile neutropenia. UDENYCA® offers three patient-friendly administration options—autoinjector (AI), on-body injector (OBI), and prefilled syringe (PFS)—providing flexibility for treatment at home, on-the-go, or in clinical settings. Since its commercial launch, over 300,000 patients have been treated with
More news about: Intas Pharmaceuticals Ltd
Aug 05, 2025, 16:05 ET ADC Therapeutics to Host Second Quarter 2025 Financial Results Conference Call on August 12, 2025
LOTIS-7 data presented at EHA and ICML and future compendia and regulatory strategy and opportunity; the timing of the PFS events for LOTIS-5 and the results of the trial and full FDA approval; the Company's ability to grow ZYNLONTA® revenue
More news about: ADC Therapeutics SA
Aug 05, 2025, 16:05 ET Jazz Pharmaceuticals Announces Second Quarter 2025 Financial Results and Updates 2025 Financial Guidance
HERIZON-GEA-01 trial and upcoming PDUFA dates for dordaviprone and Zepzelca." Key Highlights Top-line PFS data from zanidatamab in Phase 3 1L GEA expected in 4Q25.Ziihera® granted conditional marketing authorization by the European
More news about: Jazz Pharmaceuticals plc
Aug 05, 2025, 16:05 ET Jazz Pharmaceuticals Announces Second Quarter 2025 Financial Results and Updates 2025 Financial Guidance
HERIZON-GEA-01 trial and upcoming PDUFA dates for dordaviprone and Zepzelca." Key Highlights Top-line PFS data from zanidatamab in Phase 3 1L GEA expected in 4Q25.Ziihera® granted conditional marketing authorization by the European
More news about: Jazz Pharmaceuticals plc
Aug 05, 2025, 06:00 ET IDEAYA Biosciences, Inc. Reports Second Quarter 2025 Financial Results and Provides Business Update
Phase 2/3 trial of the darovasertib and crizotinib combination in 1L HLA-A2-negative metastatic uveal melanoma (MUM) on track to report median PFS data by year-end 2025; potential to enable a U.S. accelerated approval filingFirst-reported median overall survival data in over 40 1L MUM patients
More news about: IDEAYA Biosciences, Inc.
Aug 01, 2025, 16:05 ET ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
LOTIS-7 data presented at EHA and ICML and future compendia and regulatory strategy and opportunity; the timing of the PFS events for LOTIS-5 and the results of the trial and full FDA approval; the Company's ability to grow ZYNLONTA® revenue
More news about: ADC Therapeutics SA
Jul 31, 2025, 07:44 ET AbbVie Reports Second-Quarter 2025 Financial Results
data from the Phase 3 AMPLIFY trial which demonstrated that the combination regimen of Venclexta and acalabrutinib improved progression-free survival (PFS) compared to standard chemoimmunotherapy in previously untreated patients with CLL. At the American Society of Clinical Oncology (ASCO)
More news about: AbbVie
Jul 29, 2025, 17:31 ET Triple-Negative Breast Cancer Market Gearing Up for Impressive Growth at a CAGR of 4.7% During the Forecast Period (2025-2034) | DelveInsight
govitecan-hziy). The study achieved its primary goal by showing a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to chemotherapy in patients with first-line metastatic triple-negative breast cancer (mTNBC) who are not eligible for PD-1/PD-L1 inhibitors,
More news about: DelveInsight Business Research, LLP
Jul 29, 2025, 15:46 ET Biotech Underdogs Line Up for Pivotal Shots at Game-Changing Cancer Treatments
announced that its Phase 3 VIKTORIA-1 trial met both progression-free survival (PFS) primary endpoints in patients with HR+/HER2- breast cancer without PIK3CA mutations. Gedatolisib-based combinations showed significant PFS improvements compared to standard therapies, including a 7.3-month gain for the
More news about: Equity Insider
Jul 29, 2025, 09:22 ET Hot Chili Quarterly Report Period Ending June 30, 2025
understand the information relating to the PFS, they should read the PFS Technical Report in its entirety, including all qualifications, assumptions, limitations and exclusions that relate to the information to be set out in the PFS Technical Report. The PFS Technical Report is intended to be read as
More news about: Hot Chili Limited
Jul 29, 2025, 08:00 ET AbbVie Submits for U.S. FDA Approval of Combination Treatment of VENCLEXTA® (venetoclax) and Acalabrutinib for Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL)
positive results from the Phase 3 AMPLIFY trial.1 The combination regimen of VENCLEXTA and acalabrutinib improved progression-free survival (PFS) compared to standard chemoimmunotherapy in previously untreated patients with CLL.2 "This FDA submission marks a milestone for CLL
More news about: AbbVie
Jul 29, 2025, 06:45 ET Lilly's Jaypirca (pirtobrutinib), the first and only approved non-covalent (reversible) BTK inhibitor, met its primary endpoint in a head-to-head Phase 3 trial versus Imbruvica (ibrutinib) in CLL/SLL
with a nominal P-value for superiority1 (p <0.05). Progression free survival (PFS), a key secondary endpoint, was not yet mature at this analysis, but was trending in favor of pirtobrutinib. A formal PFS analysis testing for superiority is planned at a future analysis. No detriment was observed
More news about: Eli Lilly and Company
Jul 29, 2025, 04:00 ET WuXi Biologics Singapore CRDMO Hub Advances with the Launch of Modular Drug Product Facility Fabrication
Science and Technology (MSAT) labs, significantly enhancing the company's end-to-end DP services capabilities. Equipped with three pre-filled syringe (PFS) production lines and two vial production lines for both liquid and lyophilized products, it will deliver integrated DP manufacturing services — across
More news about: WuXi Biologics
Jul 28, 2025, 07:00 ET DEFENSE METALS SETTLES DEBT WITH HATCH THROUGH EQUITY
Rupert, the closest major North American port to Asia. The Company recently completed a Preliminary Feasibility Study (PFS) that demonstrated the robust economics of the project. For further information, please visit
More news about: Defense Metals Corp.
Jul 24, 2025, 21:00 ET Leads Biolabs Lists on HKEX, Raising USD 189 Million Through Initial Public Offering
substantially outperformed historical benchmarks for chemotherapy alone, which typically show ORR in the 30–55% range. While progression-free survival (PFS) data were not yet mature at the April 15, 2025 cutoff (median follow-up: 8.2 months), all dose cohorts showed favorable
More news about: Leads Biolabs
Jul 23, 2025, 18:38 ET Franco-Nevada Announces Acquisition of 1.0% NSR on AngloGold's Arthur Gold Project in Nevada
on advancing a PFS for the project with expected completion by the end of 2025 or early 2026. The Arthur Gold Project is envisioned as a large oxide project with both heap leach and milling operations. The project is a Tier-1 opportunity for AngloGold. In addition to completing a PFS, key priorities
More news about: Franco-Nevada Corporation
Jul 23, 2025, 09:37 ET U.S. Department of Defense Awards $6.2M to Golden Metal Resources for the Pilot Mountain Project
our first major milestone for the company in 2025. "This funding will unlock our ability to put forth a robust pre-feasibility study (PFS) which will detail the scope of Pilot Mountain and help us advance the Project towards our ultimate goal of being the newest domestic producer of this
More news about: Guardian Metal Resources
Jul 23, 2025, 09:24 ET U.S. Department of Defense Awards $6.2M to Golden Metal Resources for the Pilot Mountain Project
our first major milestone for the company in 2025. "This funding will unlock our ability to put forth a robust pre-feasibility study (PFS) which will detail the scope of Pilot Mountain and help us advance the Project towards our ultimate goal of being the newest domestic producer of this
More news about: Guardian Metal Resources
Jul 22, 2025, 08:00 ET Diakonos Oncology Announces First Patient Dosed in Phase 2 Clinical Trial Evaluating DOC1021 (dubodencel) for Glioblastoma
primary outcome measure is overall survival (OS), with 1-, 2- and 3-year survival as secondary outcome measures, along with progression-free survival (PFS), number of adverse events, health-related quality of life, and neuro-cognitive function. "As Diakonos' CDMO partner, we're thrilled to see this
More news about: Diakonos Oncology
Jul 22, 2025, 05:13 ET WuXi Biologics Secures FDA PLI Approval for Five Facilities, First for Commercial PFS Line
WuXi Biologics' pre-filled syringes (PFS) commercial production line passed its first FDA inspection, paving the way for global delivery of high-quality PFS solutions to clients worldwideReinforces WuXi Biologics' strong track record of a 100% success rate passing PLIs
More news about: WuXi Biologics
Jul 21, 2025, 06:30 ET Nuvalent Announces Initiation of ALKAZAR Phase 3 Randomized, Controlled Trial Evaluating Neladalkib for Patients with TKI-naïve ALK-positive NSCLC
and alignment with global regulatory agencies. The primary endpoint is progression free survival (PFS) based on Blinded Independent Central Review (BICR). Secondary endpoints include overall survival, PFS based on investigator's assessment, time to intracranial response, and BICR assessment of intracranial
More news about: Nuvalent, Inc.